These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16432162)

  • 1. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
    Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
    Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy.
    Wu G; Barth RF; Yang W; Chatterjee M; Tjarks W; Ciesielski MJ; Fenstermaker RA
    Bioconjug Chem; 2004; 15(1):185-94. PubMed ID: 14733599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
    Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
    Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent.
    Barth RF; Wu G; Yang W; Binns PJ; Riley KJ; Patel H; Coderre JA; Tjarks W; Bandyopadhyaya AK; Thirumamagal BT; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):899-903. PubMed ID: 15308165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors.
    Yang W; Barth RF; Wu G; Huo T; Tjarks W; Ciesielski M; Fenstermaker RA; Ross BD; Wikstrand CJ; Riley KJ; Binns PJ
    J Neurooncol; 2009 Dec; 95(3):355-365. PubMed ID: 19588228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents.
    Yang W; Barth RF; Wu G; Tjarks W; Binns P; Riley K
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S328-31. PubMed ID: 19467880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
    Yang W; Wu G; Barth RF; Swindall MR; Bandyopadhyaya AK; Tjarks W; Tordoff K; Moeschberger M; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2008 Feb; 14(3):883-91. PubMed ID: 18245552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas.
    Barth RF; Yang W; Adams DM; Rotaru JH; Shukla S; Sekido M; Tjarks W; Fenstermaker RA; Ciesielski M; Nawrocky MM; Coderre JA
    Cancer Res; 2002 Jun; 62(11):3159-66. PubMed ID: 12036929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.
    Barth RF; Wu G; Meisen WH; Nakkula RJ; Yang W; Huo T; Kellough DA; Kaumaya P; Turro C; Agius LM; Kaur B
    Onco Targets Ther; 2016; 9():2769-81. PubMed ID: 27274273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
    Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
    Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Ciesielski MJ; Fenstermaker RA; Moffat BA; Ross BD; Wikstrand CJ
    Clin Cancer Res; 2005 Jan; 11(1):341-50. PubMed ID: 15671565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas.
    Yang W; Barth RF; Wu G; Bandyopadhyaya AK; Thirumamagal BT; Tjarks W; Binns PJ; Riley K; Patel H; Coderre JA; Ciesielski MJ; Fenstermaker RA
    Appl Radiat Isot; 2004 Nov; 61(5):981-5. PubMed ID: 15308179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Kawabata S; Sferra TJ; Bandyopadhyaya AK; Tjarks W; Ferketich AK; Moeschberger ML; Binns PJ; Riley KJ; Coderre JA; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2006 Jun; 12(12):3792-802. PubMed ID: 16778107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.
    Gong H; Kovar JL; Cheung L; Rosenthal EL; Olive DM
    Cancer Biol Ther; 2014 Feb; 15(2):185-93. PubMed ID: 24100437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
    Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody.
    Schechter NR; Yang DJ; Azhdarinia A; Kohanim S; Wendt R; Oh CS; Hu M; Yu DF; Bryant J; Ang KK; Forster KM; Kim EE; Podoloff DA
    Anticancer Drugs; 2003 Jan; 14(1):49-56. PubMed ID: 12544258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent.
    Yang W; Barth RF; Leveille R; Adams DM; Ciesielski M; Fenstermaker RA; Capala J
    J Neurooncol; 2001 Oct; 55(1):19-28. PubMed ID: 11804279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detecting epidermal growth factor receptor tumor activity in vivo during cetuximab therapy of murine gliomas.
    Gibbs-Strauss SL; Samkoe KS; O'Hara JA; Davis SC; Hoopes PJ; Hasan T; Pogue BW
    Acad Radiol; 2010 Jan; 17(1):7-17. PubMed ID: 19796971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
    Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.